BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World J Gastroenterol 2014; 20(32): 11095-11115 [PMID: 25170198 DOI: 10.3748/wjg.v20.i32.11095] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
2 Romagnoli R, Martini S, Tandoi F, Dell Olio D, Magistroni P, Bertinetto FE, Dametto E, Rizzetto M, Salizzoni M, Amoroso A. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016;29:1070-84. [DOI: 10.1111/tri.12795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother. 2015;49:674-687. [PMID: 25770114 DOI: 10.1177/1060028015576180] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
4 Abdel-Wahab M, Abdel-Khalek EE, El-Gilany AH, Yassen AM, Al-Shobari M, Shiha U, Ali M, Sadani M, Salah T, Sultan AM, Elghawalby AN, Elmorshedi M, Al-Refaey AK, Abdalla U. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience. Arab J Gastroenterol 2017;18:151-5. [PMID: 28958486 DOI: 10.1016/j.ajg.2017.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Oliver M, Ortiz CC, Ortiz J. Challenging hepatitis C-infected liver transplant patients. Hepat Med 2016;8:1-8. [PMID: 26889091 DOI: 10.2147/HMER.S96110] [Reference Citation Analysis]
6 Grüner N, Gerbes A. [Direct-acting antiviral treatment of chronic hepatitis C infection]. MMW Fortschr Med 2015;157:57-60. [PMID: 26012687 DOI: 10.1007/s15006-015-3035-0] [Reference Citation Analysis]
7 Dawood RM, Salum GM, Abd El-Meguid M, Shemis M, Abdel Aziz AO, El Awady MK. Recipient interleukin 6 gene polymorphism and expression predict HCV recurrence post liver transplantation. Gene 2020;754:144887. [PMID: 32534059 DOI: 10.1016/j.gene.2020.144887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, Carmody I, Cohen A, Joshi S, Seal J, Sonnier D, Therapondos G, Girgrah N, Anders S, Loss GE. Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care. Liver Transpl. 2020;. [PMID: 33098277 DOI: 10.1002/lt.25925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Keller J, Marklin G, Okoye O, Desai R, Sura T, Jain A, Varma C, Nazzal M. Treatment of Hepatitis C Post-Liver Transplantation Could Mitigate Discard Rates of Hepatitis C-Positive Deceased Donor Livers and Expand the Donor Pool. J Transplant 2021;2021:6612453. [PMID: 33564467 DOI: 10.1155/2021/6612453] [Reference Citation Analysis]
10 Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CHD, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG. Increased survival in hepatitis c patients who underwent living donor liver transplant: a case-control study with propensity score matching. Ann Surg Treat Res 2017;93:293-9. [PMID: 29250507 DOI: 10.4174/astr.2017.93.6.293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Dalla E, Bulfoni M, Cesselli D, Pravisani R, Hidaka M, Eguchi S, Baccarani U. Reinfection of Transplanted Livers in HCV- and HCV/HIV-Infected Patients Is Characterized by a Different MicroRNA Expression Profile. Cells 2022;11:690. [DOI: 10.3390/cells11040690] [Reference Citation Analysis]
12 Berenguer M, Agarwal K, Burra P, Manns M, Samuel D. The road map toward an hepatitis C virus-free transplant population. Am J Transplant 2018;18:2409-16. [PMID: 29935050 DOI: 10.1111/ajt.14976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Baganate F, Beal EW, Tumin D, Azoulay D, Mumtaz K, Black SM, Washburn K, Pawlik TM. Early mortality after liver transplantation: Defining the course and the cause. Surgery 2018;164:694-704. [DOI: 10.1016/j.surg.2018.04.039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
14 Hsiao CY, Ho MC, Ho CM, Wu YM, Lee PH, Hu RH. Long-Term Tacrolimus Blood Trough Level and Patient Survival in Adult Liver Transplantation. J Pers Med 2021;11:90. [PMID: 33535628 DOI: 10.3390/jpm11020090] [Reference Citation Analysis]
15 Kuo HT, Lum E, Martin P, Bunnapradist S. Effect of diabetes and acute rejection on liver transplant outcomes: An analysis of the organ procurement and transplantation network/united network for organ sharing database. Liver Transpl 2016;22:796-804. [PMID: 26850091 DOI: 10.1002/lt.24414] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
16 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
17 Pyrsopoulos N, Trilianos P, Lingiah VA, Fung P, Punnoose M. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Eur J Gastroenterol Hepatol 2018;30:761-5. [PMID: 29481384 DOI: 10.1097/MEG.0000000000001101] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
18 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
19 Nair SP, Marella HK, Maliakkal B, Snyder H, Handley C, Kothadia JP, Ali B, Satapathy SK, Molnar MZ, Clark I, Jain R, Helmick R, Eymard C, Eason JD. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome. Clin Transplant 2021;35:e14281. [PMID: 33690929 DOI: 10.1111/ctr.14281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Cieciura T, Urbanowicz A, Foroncewicz B, Hryniewiecka E, Pączek L, Ciszek M. Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals. Transplant Proc 2020;52:2450-3. [PMID: 32241637 DOI: 10.1016/j.transproceed.2020.01.098] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]